Advertisement

Current Rheumatology Reports

, Volume 13, Issue 1, pp 28–36 | Cite as

A Unifying Hypothesis for Scleroderma: Identifying a Target Cell for Scleroderma

  • William M. MahoneyJr
  • Jo Nadine Fleming
  • Stephen M. SchwartzEmail author
Article

Abstract

We propose that a recent change in the conception of the role of type 1 interferon and the identification of adventitial stem cells suggests a unifying hypothesis for scleroderma. This hypothesis begins with vasospasm. Vasospasm is fully reversible unless, as proposed here, the resulting ischemia leads to apoptosis and activation of type 1 interferon. The interferon, we propose, initiates immune amplification, including characteristic scleroderma-specific antibodies. We propose that the interferon also acts on adventitial stem cells, producing myofibroblasts, rarefaction, and intimal hyperplasia—three morphologic changes that characterize this disease. Regulator of G-protein signaling 5 (RGS5), a regulator of vasoactive G-protein–coupled receptors, is a cell type–specific marker of pericytes and scleroderma myofibroblasts. RGS5 may provide a key link between initial hyperplasia and fibrosis in this disease.

Keywords

Type 1 interferon Vasculopathy Fibrosis Adventitial stem cell RGS5 

Notes

Acknowledgment

Drs. Mahoney, Fleming, and Schwartz have received grant support from the Scleroderma Research Foundation.

Disclosure

No potential conflicts of interest relevant to this article were reported.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Nash RA, McSweeney PA, Crofford LJ, et al.: High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 2007, 110:1388–1396.CrossRefPubMedGoogle Scholar
  2. 2.
    Hansen-Smith F, Greene AS, Cowley AW Jr, Lombard JH: Structural changes during microvascular rarefaction in chronic hypertension. Hypertension 1990, 15:922–928.PubMedGoogle Scholar
  3. 3.
    Vracko R: A comparison of the microvascular lesions in diabetes mellitus with those in normal aging. J Am Geriatr Soc 1982, 30:201–205.PubMedGoogle Scholar
  4. 4.
    Lind L, Lithell H: Decreased peripheral blood flow in the pathogenesis of the metabolic syndrome comprising hypertension, hyperlipidemia, and hyperinsulinemia. Am Heart J 1993, 125:1494–1497.CrossRefPubMedGoogle Scholar
  5. 5.
    Benjamin LE, Hemo I, Keshet E: A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998, 125:1591–1598.PubMedGoogle Scholar
  6. 6.
    •• Fleming JN, Nash RA, McLeod DO, et al.: Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS One 2008, 3:e1452. This article identified key markers of the SSc-associated vasculopathy in humans (VE-cadherin, IFN-α, and RGS5). Importantly, analysis of patients following bone marrow stem cell transplantation demonstrated that the capillary rarefaction was reversed and the expression of the vasculopathy markers all returned to normal. CrossRefPubMedGoogle Scholar
  7. 7.
    Fleming JN, Nash RA, Mahoney WM Jr, Schwartz SM: Is scleroderma a vasculopathy? Curr Rheumatol Rep 2009, 11:103–110.CrossRefPubMedGoogle Scholar
  8. 8.
    • Nakanishi Y, Henson PM, Shiratsuchi A: Pattern recognition in phagocytic clearance of altered self. Adv Exp Med Biol 2009, 653:129–138. This article demonstrated that an unexpected off-target effect of apoptotic debris is damage to the surrounding tissue, resulting in a feed-forward activation of the immune response. CrossRefPubMedGoogle Scholar
  9. 9.
    Erwig LP, Henson PM: Immunological consequences of apoptotic cell phagocytosis. Am J Pathol 2007, 171:2–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Derrett-Smith EC, Dooley A, Khan K, et al.: Systemic vasculopathy with altered vasoreactivity in a transgenic mouse model of scleroderma. Arthritis Res Ther 2010, 12:R69.CrossRefPubMedGoogle Scholar
  11. 11.
    Wilson MS, Wynn TA: Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol 2009, 2:103–121.CrossRefPubMedGoogle Scholar
  12. 12.
    • Kim D, Peck A, Santer D, et al.: Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis. Arthritis Rheum 2008, 58:2163–2173. This article demonstrates the connection between high IFN-α expression levels and an increase in pulmonary fibrosis in SSc patients. CrossRefPubMedGoogle Scholar
  13. 13.
    Stetson DB, Medzhitov R: Type I interferons in host defense. Immunity 2006, 25:373–381.CrossRefPubMedGoogle Scholar
  14. 14.
    Moser KL, Kelly JA, Lessard CJ, Harley JB: Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun 2009, 10:373–379.CrossRefPubMedGoogle Scholar
  15. 15.
    Gourh P, Agarwal SK, Divecha D, et al.: Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines. Arthritis Rheum 2009, 60:3794–3806.CrossRefPubMedGoogle Scholar
  16. 16.
    Solans R, Bosch JA, Esteban I, Vilardell M: Systemic sclerosis developing in association with the use of interferon alpha therapy for chronic viral hepatitis. Clin Exp Rheumatol 2004, 22:625–628.PubMedGoogle Scholar
  17. 17.
    Duan H, Fleming J, Pritchard DK, et al.: Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum 2008, 58:1465–1474.CrossRefPubMedGoogle Scholar
  18. 18.
    Bauer JW, Petri M, Batliwalla FM, et al.: Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum 2009, 60:3098–3107.CrossRefPubMedGoogle Scholar
  19. 19.
    Wang J, Nash RA, Chu B, et al.: Improvements in digital vasculature observed using micro magnetic resonance angiography after high-dose immunosuppression for severe systemic sclerosis. Bone Marrow Transplant 2009, 44:387–389.CrossRefPubMedGoogle Scholar
  20. 20.
    Hui DY: Intimal hyperplasia in murine models. Curr Drug Targets 2008, 9:251–260.CrossRefPubMedGoogle Scholar
  21. 21.
    Schwartz SM, Murry CE: Proliferation and the monoclonal origins of atherosclerotic lesions. Annu Rev Med 1998, 49:437–460.CrossRefPubMedGoogle Scholar
  22. 22.
    D’Angelo WA, Fries JF, Masi AT, Shulman LE: Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969, 46:428–440.CrossRefPubMedGoogle Scholar
  23. 23.
    Leroy EC: The vascular defect in scleroderma (systemic sclerosis). Acta Med Scand Suppl 1987, 715:165–167.PubMedGoogle Scholar
  24. 24.
    Folkow B, Grimby G, Thulesius O: Adaptive structural changes of the vascular walls in hypertension and their relation to the control of the peripheral resistance. Acta Physiol Scand 1958, 44:255–272.CrossRefPubMedGoogle Scholar
  25. 25.
    Slomp J, van Munsteren JC, Poelmann RE, et al.: Formation of intimal cushions in the ductus arteriosus as a model for vascular intimal thickening. An immunohistochemical study of changes in extracellular matrix components. Atherosclerosis 1992, 93:25–39.CrossRefPubMedGoogle Scholar
  26. 26.
    Shimokawa H, Takeshita A: Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 2005, 25:1767–1775.CrossRefPubMedGoogle Scholar
  27. 27.
    Fleming JN, Shulman HM, Nash RA, et al.: Cutaneous chronic graft-versus-host disease does not have the abnormal endothelial phenotype or vascular rarefaction characteristic of systemic sclerosis. PLoS One 2009, 4:e6203.CrossRefPubMedGoogle Scholar
  28. 28.
    Siracusa LD, Christner P, McGrath R, et al.: The tight skin (Tsk) mutation in the mouse, a model for human fibrotic diseases, is tightly linked to the beta 2-microglobulin (B2m) gene on chromosome 2. Genomics 1993, 17:748–751.CrossRefPubMedGoogle Scholar
  29. 29.
    Clark SH: Animal models in scleroderma. Curr Rheumatol Rep 2005, 7:150–155.CrossRefPubMedGoogle Scholar
  30. 30.
    Claman HN, Jaffee BD, Huff JC, Clark RA: Chronic graft-versus-host disease as a model for scleroderma. II. Mast cell depletion with deposition of immunoglobulins in the skin and fibrosis. Cell Immunol 1985, 94:73–84.CrossRefPubMedGoogle Scholar
  31. 31.
    Sgonc R, Gruschwitz MS, Dietrich H, et al.: Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996, 98:785–792.CrossRefPubMedGoogle Scholar
  32. 32.
    Schwartz SM: Smooth muscle migration in atherosclerosis and restenosis. J Clin Invest 1997, 100:S87–S89.PubMedGoogle Scholar
  33. 33.
    Wilcox JN, Cipolla GD, Martin FH, et al.: Contribution of adventitial myofibroblasts to vascular remodeling and lesion formation after experimental angioplasty in pig coronary arteries. Ann N Y Acad Sci 1997, 811:437–447.CrossRefPubMedGoogle Scholar
  34. 34.
    Zalewski A, Shi Y, Johnson AG: Diverse origin of intimal cells: smooth muscle cells, myofibroblasts, fibroblasts, and beyond? Circ Res 2002, 91:652–655.CrossRefPubMedGoogle Scholar
  35. 35.
    •• Passman JN, Dong XR, Wu SP, et al.: A sonic hedgehog signaling domain in the arterial adventitia supports resident Sca1+ smooth muscle progenitor cells. Proc Natl Acad Sci U S A 2008, 105: 9349–9354. This article identifies a novel stem cell niche in the vessel wall, the ASC, which is responsive to Hh-mediated signaling and expresses common progenitor genes, including Sca1 and Klf4. CrossRefPubMedGoogle Scholar
  36. 36.
    •• Lavine KJ, Long F, Choi K, et al.: Hedgehog signaling to distinct cell types differentially regulates coronary artery and vein development. Development 2008, 135:3161–3171. This article is one of a series from this group that examines the role of Hh in the development and maintenance of the coronary vasculature. The authors have identified that cardiomyoblast-derived Hh supports the development of coronary veins, while adventitial/perivascular-derived Hh supports the development of coronary arteries. CrossRefPubMedGoogle Scholar
  37. 37.
    •• Gaengel K, Genove G, Armulik A, Betsholtz C: Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler Thromb Vasc Biol 2009, 29:630–638. This article characterizes the function of pericytes in vessel stabilization and the role of pericytes in controlling EC/pericyte cross-talk. CrossRefPubMedGoogle Scholar
  38. 38.
    Stein I, Neeman M, Shweiki D, et al.: Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes. Mol Cell Biol 1995, 15:5363–5368.PubMedGoogle Scholar
  39. 39.
    Lindahl P, Johansson BR, Leveen P, Betsholtz C: Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997, 277:242–245.CrossRefPubMedGoogle Scholar
  40. 40.
    Grunewald M, Avraham I, Dor Y, et al.: VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 2006, 124:175–189.CrossRefPubMedGoogle Scholar
  41. 41.
    • Diaz-Flores L, Gutierrez R, Madrid JF, et al.: Pericytes. Morphofunction, interactions and pathology in a quiescent and activated mesenchymal cell niche. Histol Histopathol 2009, 24:909–969. This review extensively summarizes the morphologic and molecular expression pattern observed in pericytes. PubMedGoogle Scholar
  42. 42.
    Sela S, Itin A, Natanson-Yaron S, et al.: A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ Res 2008, 102:1566–1574.CrossRefPubMedGoogle Scholar
  43. 43.
    Adams LD, Geary RL, McManus B, Schwartz SM: A comparison of aorta and vena cava medial message expression by cDNA array analysis identifies a set of 68 consistently differentially expressed genes, all in aortic media. Circ Res 2000, 87:623–631.PubMedGoogle Scholar
  44. 44.
    Bondjers C, Kalen M, Hellstrom M, et al.: Transcription profiling of platelet-derived growth factor-B-deficient mouse embryos identifies RGS5 as a novel marker for pericytes and vascular smooth muscle cells. Am J Pathol 2003, 162:721–729.PubMedGoogle Scholar
  45. 45.
    Mitchell TS, Bradley J, Robinson GS, et al.: RGS5 expression is a quantitative measure of pericyte coverage of blood vessels. Angiogenesis 2008, 11:141–151.CrossRefPubMedGoogle Scholar
  46. 46.
    •• Hamzah J, Jugold M, Kiessling F, et al.: Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 2008, 453:410–414. This article demonstrates that RGS5-null tumors have “leaky” vasculature, implying that pericyte expression of RGS5 regulates vascular stability. CrossRefPubMedGoogle Scholar
  47. 47.
    Hollinger S, Hepler JR: Cellular regulation of RGS proteins: modulators and integrators of G protein signaling. Pharmacol Rev 2002, 54:527–559.CrossRefPubMedGoogle Scholar
  48. 48.
    • Nisancioglu MH, Mahoney WM Jr, Kimmel DD, et al.: Generation and characterization of rgs5 mutant mice. Mol Cell Biol 2008, 28:2324–2331. This article demonstrates that RGS5 is expressed in pericytes supporting neovessels, and in the absence of RGS5 expression, mice are hypotensive. CrossRefPubMedGoogle Scholar
  49. 49.
    Cho H, Park C, Hwang IY, et al.: Rgs5 targeting leads to chronic low blood pressure and a lean body habitus. Mol Cell Biol 2008, 28:2590–2597.CrossRefPubMedGoogle Scholar
  50. 50.
    Trojanowska M: Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology (Oxford) 2008, 47(Suppl 5):v2–v4.CrossRefGoogle Scholar
  51. 51.
    Akhmetshina A, Venalis P, Dees C, et al.: Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009, 60:219–224.CrossRefPubMedGoogle Scholar
  52. 52.
    Baroni SS, Santillo M, Bevilacqua F, et al.: Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006, 354:2667–2676.CrossRefPubMedGoogle Scholar
  53. 53.
    Tellides G, Pober JS: Interferon-gamma axis in graft arteriosclerosis. Circ Res 2007, 100:622–632.CrossRefPubMedGoogle Scholar
  54. 54.
    • Li Z, Wang ZG, Bian C, et al.: Interferon regulatory factor-1 exerts inhibitory effect on neointimal formation after vascular injury. Chin Med Sci J 2009, 24:91–96. This article demonstrates that IRF1-null mice have larger neointimas following femoral artery constriction, implying that IRF1 signals SMCs to undergo apoptosis. CrossRefPubMedGoogle Scholar
  55. 55.
    Shen H, Zhang M, Minuk GY, Gong Y: Different effects of rat interferon alpha, beta and gamma on rat hepatic stellate cell proliferation and activation. BMC Cell Biol 2002, 3:9.CrossRefPubMedGoogle Scholar
  56. 56.
    • Schirmer SH, Fledderus JO, Bot PT, et al.: Interferon-beta signaling is enhanced in patients with insufficient coronary collateral artery development and inhibits arteriogenesis in mice. Circ Res 2008, 102:1286–1294. This article identified type 1 IFN, specifically IFN-β, as a key determinant of collateral development (arteriogenesis). Patients with low IFN-β expression levels developed more collaterals than those in which IFN-β was induced. The authors correlated the in vivo observations with in vitro experiments demonstrating that IFN-β inhibits SMC proliferation. CrossRefPubMedGoogle Scholar
  57. 57.
    Stout AJ, Gresser I, Thompson WD: Inhibition of wound healing in mice by local interferon alpha/beta injection. Int J Exp Pathol 1993, 74:79–85.PubMedGoogle Scholar
  58. 58.
    • Eloranta ML, Franck-Larsson K, Lovgren T, et al.: Type I interferon system activation and association with disease manifestations in systemic sclerosis. Ann Rheum Dis 2010, 69:1396–1402. This article correlated type 1 IFN expression, specifically IFN-α, with SSc disease progression. The authors correlated increased IFN-α expression, produced by plasmacytoid dendritic cells, with the progressive pulmonary fibrosis and the digital ulcers/vascular rarefaction observed in SSc patients. CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • William M. MahoneyJr
    • 1
  • Jo Nadine Fleming
    • 1
  • Stephen M. Schwartz
    • 1
    Email author
  1. 1.Department of Pathology, Center for Cardiovascular BiologyUniversity of Washington School of MedicineSeattleUSA

Personalised recommendations